Andrew Reardon, CLO & Secretary at LIGAND PHARMACEUTICALS INC (LGND), sold 5,000 shares at $302.51 ($1.5M) on 2026-10-02, disclosed to the SEC on 2026-10-06.
Scheduled sale ($1.5M) by CLO & Secretary under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $302.51 | 833 | $252K | 16.6% |
| 2 | $303.54 | 1,976 | $600K | 39.5% |
| 3 | $304.52 | 1,535 | $467K | 30.7% |
| 4 | $306.18 | 404 | $124K | 8.1% |
| 5 | $307.19 | 235 | $72K | 4.7% |
| 6 | $307.74 | 17 |
| $5K |
| 0.3% |
| Total | $304.07 avg | 5,000 | $1.5M | 100% |
| Filing → |
| LGND | SELL | 2026-07-06 | $1.6M | — | Filing → |
| LGND | SELL | 2026-06-02 | $1.1M | — | Filing → |
| LGND | SELL | 2026-05-04 | $1.2M | — | Filing → |